This application proposed to develop novel antibody-drug conjugates (ADCs) targeting a circulating tumor cells (CTCs)-associated antigen. By selectively killing CTCs through the delivered cytotoxic drugs, ADCs promise to eliminate brain metastasis-initiating CTCs and primary tumors shedding CTCs. If successful, this work will provide first-in-class targeted therapeutics for combating metastatic cancer and lead to a paradigm shift in cancer treatment.
